We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+18.77%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.81B
AUM Growth
+$81.2M
Cap. Flow
-$98.4M
Cap. Flow %
-1.69%
Top 10 Hldgs %
85.45%
Holding
128
New
20
Increased
23
Reduced
35
Closed
17
Avg Time Held Equity + Options
4.5 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
4.4 quarters
Avg Time Held Equity only
5.5 quarters
Top 10 Avg Time Held Equity only
6.1 quarters
Top 20 Avg Time Held Equity only
7.1 quarters

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.13M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.85M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.62M
4
PRQR icon
ProQR Therapeutics
PRQR
+$5.19M
5
ARRY icon
Array Biopharma Inc
ARRY
+$5.11M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$15M
3
ONC icon
BeOne Medicines Ltd
ONC
+$13M
4
BLUE icon
bluebird bio
BLUE
+$12.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.79%
2 Consumer Discretionary 22.09%
3 Healthcare 21.97%
4 Miscellaneous 13.15%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARRY icon
26
DELISTED
Array Biopharma Inc
ARRY
$18.4M 0.32%
1,500,000
+550,000
+58% +$5.11M
2013 Q2
17 quarters
INCY icon
27
CALL
Incyte
INCY
$22.9B
$17.5M 0.3%
150,000
-50,000
-25% -$6.33M
2017 Q2
1 quarter
FOLD icon
28
CALL
DELISTED
Amicus Therapeutics
FOLD
$15.1M 0.26%
1,000,000
+500,000
+100% +$6.61M
2017 Q2
1 quarter
MS icon
29
CALL
Morgan Stanley
MS
$298B
$14.5M 0.25%
300,000
-200,000
-40% -$9.28M
2017 Q2
1 quarter
NKTR icon
30
CALL
Nektar Therapeutics
NKTR
$1.41B
$14.4M 0.25%
40,000
-26,667
-40% -$8.34M
2016 Q4
3 quarters
RDUS icon
31
CALL
DELISTED
Radius Health, Inc.
RDUS
$13.5M 0.23%
350,000
+150,000
+75% +$5.89M
2017 Q2
1 quarter
TER icon
32
CALL
Teradyne
TER
$63B
$13.1M 0.22%
350,000
-150,000
-30% -$5.19M
2017 Q2
1 quarter
IRWD icon
33
Ironwood Pharmaceuticals
IRWD
$631M
$12.9M 0.22%
975,354
+238,800
+32% +$3.29M
2013 Q2
17 quarters
WUBA
34
CALL
DELISTED
58.com Inc
WUBA
$12.6M 0.22%
+200,000
New +$11.4M
2017 Q3
0 quarters
ARRY icon
35
CALL
DELISTED
Array Biopharma Inc
ARRY
$12.3M 0.21%
1,000,000
+500,000
+100% +$4.64M
2017 Q2
1 quarter
AVXS
36
DELISTED
AveXis, Inc. Common Stock
AVXS
$11.6M 0.2%
120,000
-20,000
-14% -$1.8M
2016 Q1
6 quarters
RXDX
37
DELISTED
Ignyta, Inc.
RXDX
$11.1M 0.19%
900,000
– –
2014 Q1
14 quarters
MDCO
38
DELISTED
Medicines Co
MDCO
$11.1M 0.19%
300,000
-50,000
-14% -$1.84M
2016 Q4
3 quarters
AGEN icon
39
Agenus
AGEN
$346M
$11M 0.19%
127,375
+25,475
+25% +$2.06M
2013 Q2
17 quarters
FOLD icon
40
DELISTED
Amicus Therapeutics
FOLD
$10.6M 0.18%
700,000
-700,000
-50% -$9.26M
2016 Q2
5 quarters
ATRA icon
41
Atara Biotherapeutics
ATRA
$95.2M
$9.93M 0.17%
24,000
+4,000
+20% +$1.51M
2016 Q3
4 quarters
TSRO
42
DELISTED
TESARO, Inc.
TSRO
$9.68M 0.17%
75,000
+25,000
+50% +$3.1M
2017 Q1
2 quarters
RDUS icon
43
DELISTED
Radius Health, Inc.
RDUS
$9.64M 0.17%
250,000
+100,000
+67% +$3.93M
2016 Q2
5 quarters
CLVS
44
DELISTED
Clovis Oncology, Inc.
CLVS
$9.48M 0.16%
115,000
+90,000
+360% +$7.13M
2017 Q2
1 quarter
SAGE icon
45
DELISTED
Sage Therapeutics
SAGE
$9.35M 0.16%
150,000
+60,000
+67% +$4.71M
2016 Q3
4 quarters
GBT
46
DELISTED
Global Blood Therapeutics, Inc.
GBT
$9.31M 0.16%
300,000
+200,000
+200% +$5.62M
2016 Q2
5 quarters
BMRN icon
47
CALL
BioMarin Pharmaceuticals
BMRN
$10.6B
$9.31M 0.16%
100,000
-50,000
-33% -$4.42M
2016 Q4
3 quarters
SRPT icon
48
Sarepta Therapeutics
SRPT
$1.89B
$9.07M 0.16%
200,000
+50,000
+33% +$2M
2016 Q3
4 quarters
JUNO
49
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$8.97M 0.15%
200,000
+150,000
+300% +$5.11M
2016 Q1
6 quarters
MCRB icon
50
Seres Therapeutics
MCRB
$27.2M
$8.82M 0.15%
27,500
-2,500
-8% -$683K
2015 Q2
9 quarters
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2017 Portfolio in Review

As of Q3 2017, Artal Group held 128 positions worth $5.81B, up 1.4% from $5.72B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group's Q3 2017 filing shows 20 new, 23 increased, 35 reduced and 17 closed positions. Its largest new stake was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M. The largest sale was Goldman Sachs, an estimated $22.6M.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q3 2017 buy was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M.
  • Artal Group added most to Clovis Oncology, Inc. in Q3 2017, an estimated $7.13M increase.
  • Artal Group's biggest Q3 2017 reduction was Agios Pharmaceuticals, cutting an estimated $15M.
  • Artal Group fully exited Goldman Sachs in Q3 2017, selling an estimated $22.6M.
  • Artal Group's ten largest holdings make up 85% of its $5.81B portfolio in Q3 2017.
  • Artal Group opened 20 new positions and closed 17 in Q3 2017.
  • Artal Group's portfolio value rose 1.4% quarter-over-quarter to $5.81B.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.